image
Boston Scientific Corporation BSX
Healthcare - Medical - Devices - NYSE - US
Watchlist
$ 91.54
2.05 %
$ 135 B
Market Cap
73.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BSX stock under the worst case scenario is HIDDEN Compared to the current market price of 91.5 USD, Boston Scientific Corporation is HIDDEN

BSX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BSX stock under the base case scenario is HIDDEN Compared to the current market price of 91.5 USD, Boston Scientific Corporation is HIDDEN

BSX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BSX stock under the best case scenario is HIDDEN Compared to the current market price of 91.5 USD, Boston Scientific Corporation is HIDDEN

BSX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart BSX

image
1M -11%
6M 5%
1Y 36%
3Y 98%
5Y 161%
All
$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
16.7 B REVENUE
17.61%
Growth Rates
1Year 17.61%
3Years 12.10%
5Years 9.30%
7Years 9.19%
10Years 8.54%
2.6 B OPERATING INCOME
11.10%
Growth Rates
1Year 11.10%
3Years 8.41%
5Years 11.39%
7Years 10.61%
10Years 24.16%
1.85 B NET INCOME
15.95%
Growth Rates
1Year 15.95%
3Years 21.04%
5Years -17.05%
7Years 50.82%
10Years 33.15%
3.44 B OPERATING CASH FLOW
37.24%
Growth Rates
1Year 37.24%
3Years 22.47%
5Years 13.35%
7Years 13.38%
10Years 10.47%
-5.69 B INVESTING CASH FLOW
-120.94%
Growth Rates
1Year -120.94%
3Years -52.71%
5Years -2.44%
7Years -28.00%
10Years -22.54%
1.81 B FINANCING CASH FLOW
36180.00%
Growth Rates
1Year 36180.00%
3Years 176.31%
5Years -9.41%
7Years 49.24%
10Years 30.29%
4.56 B REVENUE
8.36%
Growth Rates
1Year 17.61%
3Years 12.10%
5Years 9.30%
7Years 9.19%
10Years 8.54%
675 M OPERATING INCOME
-7.91%
Growth Rates
1Year 11.10%
3Years 8.41%
5Years 11.39%
7Years 10.61%
10Years 24.16%
562 M NET INCOME
-19.71%
Growth Rates
1Year 15.95%
3Years 21.04%
5Years -17.05%
7Years 50.82%
10Years 33.15%
1.46 B OPERATING CASH FLOW
45.31%
Growth Rates
1Year 37.24%
3Years 22.47%
5Years 13.35%
7Years 13.38%
10Years 10.47%
-3.7 B INVESTING CASH FLOW
-159.57%
Growth Rates
1Year -120.94%
3Years -52.71%
5Years -2.44%
7Years -28.00%
10Years -22.54%
214 M FINANCING CASH FLOW
-87.25%
Growth Rates
1Year 36180.00%
3Years 176.31%
5Years -9.41%
7Years 49.24%
10Years 30.29%
Balance Sheet Boston Scientific Corporation
image
Current Assets 6.92 B
Cash & Short-Term Investments 414 M
Receivables 2.56 B
Other Current Assets 3.95 B
Non-Current Assets 32.5 B
Long-Term Investments 0
PP&E 3.29 B
Other Non-Current Assets 29.2 B
6.49 %10.02 %8.36 %74.07 %Total Assets$39.4b
Current Liabilities 6.4 B
Accounts Payable 960 M
Short-Term Debt 1.78 B
Other Current Liabilities 3.66 B
Non-Current Liabilities 11 B
Long-Term Debt 8.97 B
Other Non-Current Liabilities 2.02 B
5.52 %10.22 %21.05 %51.56 %11.64 %Total Liabilities$17.4b
EFFICIENCY
Earnings Waterfall Boston Scientific Corporation
image
Revenue 16.7 B
Cost Of Revenue 5.26 B
Gross Profit 11.5 B
Operating Expenses 8.89 B
Operating Income 2.6 B
Other Expenses 757 M
Net Income 1.85 B
18b18b16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0017b(5b)11b(9b)3b(757m)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.61% GROSS MARGIN
68.61%
Averages
1Year 68.61%
3Years 68.84%
5Years 67.90%
7Years 68.64%
10Years 69.13%
15.54% OPERATING MARGIN
15.54%
Averages
1Year 15.54%
3Years 15.00%
5Years 14.54%
7Years 14.60%
10Years 11.73%
11.06% NET MARGIN
11.06%
Averages
1Year 11.06%
3Years 9.25%
5Years 7.02%
7Years 13.70%
10Years 9.80%
8.51% ROE
8.51%
Averages
1Year 8.51%
3Years 6.92%
5Years 5.22%
7Years 11.30%
10Years 8.20%
4.70% ROA
4.70%
Averages
1Year 4.70%
3Years 3.80%
5Years 2.83%
7Years 5.36%
10Years 3.86%
6.06% ROIC
6.06%
Averages
1Year 6.06%
3Years 5.23%
5Years 5.32%
7Years 10.68%
10Years 8.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Boston Scientific Corporation
image
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.85 B
Depreciation & Amortization 1.27 B
Capital Expenditures -790 M
Stock-Based Compensation 266 M
Change in Working Capital 0
Others 54 M
Free Cash Flow 2.64 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Boston Scientific Corporation
image
Wall Street analysts predict an average 1-year price target for BSX of $90.8 , with forecasts ranging from a low of $73 to a high of $130 .
BSX Lowest Price Target Wall Street Target
73 USD -20.25%
BSX Average Price Target Wall Street Target
90.8 USD -0.79%
BSX Highest Price Target Wall Street Target
130 USD 42.01%
Price
Max Price Target
Min Price Target
Average Price Target
1301301201201101101001009090808070706060May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Boston Scientific Corporation
image
Sold
0-3 MONTHS
38.6 M USD 9
3-6 MONTHS
21.6 M USD 9
6-9 MONTHS
42.2 M USD 4
9-12 MONTHS
21.6 M USD 9
Bought
0 USD 0
0-3 MONTHS
4.51 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why Boston Scientific (BSX) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2 weeks ago
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership. zacks.com - 2 weeks ago
Boston Scientific announces conference call discussing first quarter 2025 results MARLBOROUGH, Mass. , April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. prnewswire.com - 2 weeks ago
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider Boston Scientific (BSX) reachead $100.88 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close. zacks.com - 2 weeks ago
PAHC vs. BSX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 2 weeks ago
International Expansion, Product Launches Support BSX Stock Boston Scientific continues to successfully expand its operations across various geographies outside the United States. zacks.com - 3 weeks ago
Medical Products Leader Tops These Early-Bird Buy Points Boston Scientific has the highest Composite Rating of 126 companies in the medical products industry. The post Medical Products Leader Tops These Early-Bird Buy Points appeared first on Investor's Business Daily. investors.com - 3 weeks ago
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic Boston Scientific, Abbott and Medtronic are included in this Analyst Blog. zacks.com - 3 weeks ago
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.67, denoting a +1.97% change from the preceding trading day. zacks.com - 3 weeks ago
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025. zacks.com - 3 weeks ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT. zacks.com - 3 weeks ago
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily. investors.com - 4 weeks ago
8. Profile Summary

Boston Scientific Corporation BSX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 135 B
Dividend Yield 0.00%
Description Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Contact 300 Boston Scientific Way, Marlborough, MA, 01752-1234 https://www.bostonscientific.com
IPO Date May 19, 1992
Employees 53000
Officers Ms. Emily M. Woodworth Senior Vice President, Global Controller & Chief Accounting Officer Ms. Jodi Euerle Eddy Senior Vice President and Chief Information & Digital Officer Mr. Jonathan R Monson Senior Vice President of Investor Relations Mr. Michael F. Mahoney Chairman, President & Chief Executive Officer Mr. Daniel J. Brennan CPA Executive Vice President & Chief Financial Officer Mr. John Bradley Sorenson Executive Vice President of Global Operations Mr. Jeffrey B. Mirviss M.B.A. Executive Vice President & President of Peripheral Interventions Mr. Joseph M. Fitzgerald Executive Vice President & Group President of Cardiology Mr. Vance R. Brown J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Arthur Crosswell Butcher Executive Vice President and Group President of MedSurg & Asia Pacific